PCMK
LGND icon

Paragon Capital Management (Kansas)’s Ligand Pharmaceuticals LGND Stock Holding History

Paragon Capital Management (Kansas)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-160
Closed -$13K – 272
2019
Q1 		$13K Buy
+160
New +$12.1K 0.01% 150

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Paragon Capital Management (Kansas)'s LGND Position: Q2 2019 in Review

Paragon Capital Management (Kansas) sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 160 shares — an estimated $13K sold.

Paragon Capital Management (Kansas) first reported a position in LGND in Q1 2019 and held it in 1 quarter. The position peaked at $13K in Q1 2019. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

  • Paragon Capital Management (Kansas) reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Paragon Capital Management (Kansas) sold 160 Ligand Pharmaceuticals shares in Q2 2019, an estimated $13K.
  • Paragon Capital Management (Kansas) first reported a position in Ligand Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Paragon Capital Management (Kansas)'s Ligand Pharmaceuticals position peaked at $13K in Q1 2019.
  • 305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Paragon Capital Management (Kansas)'s 13F filing for Q2 2019, filed 6 Aug 2019.